Objective To investigate the application effect of bronchial arterial chemoembolization(BACE)+recombi-nant human endostatin+programmed cell death 1(PD-1)inhibitor in patients with advanced non-small cell lung cancer(NSCLC).Method A total of 60 patients with advanced NSCLC were divided into group A(n=28)and group B(n=32)according to different treatment methods.The group A received intravenous chemotherapy+recombinant human end-ostatin+PD-1 inhibitor treatment,and the group B received BACE+recombinant human endostatin+PD-1 inhibitor treat-ment.The clinical efficacy,improvement of quality of life,level of T cell subsets(CD3+,CD4+,CD8+,CD4+/CD8+)and in-cidence of adverse reactions were compared between the two groups.Result The total effective rate and improvement rate of quality of life in group B were higher than those in group A,the total incidence of adverse reactions was lower than that in group A,and the differences were statistically significant(P＜0.05).After treatment,the CD3+,CD4+levels and CD4+/CD8+in two groups were higher than those before treatment,the CD8+levels were lower than those before treat-ment,the CD3+,CD4+levels and CD4+/CD8+in group B were higher than those in group A,the CD8+level was lower than that in group A,and the differences were statistically significant(P＜0.05).Conclusion BACE+recombinant human endostatin+PD-1 inhibitor is safe and effective in the treatment of advanced NSCLC patients,which can improve the qual-ity of life of patients and the level of T cell subsets,reduce the incidence of adverse reactions.
关键词
支气管动脉化疗栓塞术/重组人血管内皮抑制素/程序性死亡受体1抑制剂/晚期非小细胞肺癌/应用效果
Key words
bronchial arterial chemoembolization/recombinant human endostatin/programmed cell death 1 inhibi-tor/advanced non-small cell lung cancer/application effect
维普
万方数据